Clinical Trials

Endometrial Cancer Clinical Trials

Clinical trials help doctors find better ways to treat and prevent cancer. If you or a loved one has cancer, you might consider joining a clinical trial in order to try a new drug or treatment, or help doctors develop better treatments for the future. Learn more about clinical trials

Browse our list of endometrial clinical trials below, or search our clinical trials database by cancer type, drug, doctor, or protocol.

Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

LCCC1326: This is an open label, single-arm, single-center study of the addition of metformin to standard levonorgestrel-releasing intrauterine device treatment of 30 evaluable non-surgical patients with either complex atypical hyperplasia or grade 1 endometrial adenocarcinoma.

Pre-operative Window Study of Interval Exercise Training as a Therapy for Endometrial Cancer

LCCC1839: This interventional trial recruits women with endometrial cancer to participate in high intensity interval training (HIIT) prior to their standard of care surgery. The study will evaluate tissue and blood to determine if HIIT training has anti-cancer effects.

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women with Recurrent or Persistent Endometrial Cancer

NRG-GY012-CIRB: This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (refractory). Olaparib, cediranib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Testing the combinations may lower the chance of endometrial cancer growing or spreading compared to usual care.

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

NRG-GY018-CIRB:  This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.

A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

NRG-GY020-CIRB: This phase III trial compares whether the addition of pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer coming back (recurrence) in patients with newly diagnosed stage I-II endometrial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of pembrolizumab to radiation treatment may be more effective than radiation treatment alone in reducing cancer recurrence.

Surgical Window of Opportunity Study of Megestrol Acetate Compared with Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia

NWU20-02-01: This phase II trial studies the effect of megestrol acetate alone or in combination with metformin in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer. Megestrol acetate is a drug used to block estrogen and suppress the effects of estrogen and androgens. It is the current non-surgical treatment of endometrial intraepithelial neoplasia. Metformin is a drug that has been found to have anti-cancer properties. Giving metformin and megestrol acetate together may decrease the growth of endometrial intraepithelial neoplasia in the uterus better than megestrol alone.

A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer

ONC012: This is a Simon’s two-stage, non-randomized, open label, 2-arm Phase II trial of ONC201 in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen.

Clinical Trials Office

The Clinical Trials Office (CTO) supports the design and conduct of oncology clinical trials. The CTO is responsible for patient and study coordination-related activities, including subject evaluation and registration, toxicity assessment and safety monitoring of novel therapeutics and patient education.

The CTO works to assure patient eligibility and safety, regulatory compliance, and quality, reproducible data.

Learn more about the UNC Lineberger Clinical Trials Office